Neumonías adquiridas en la comunidad

  1. Resano Barrio, P.
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2018

Título del ejemplar: Enfermedades respiratorias (II)Patología infecciosa respiratoria

Serie: 12

Número: 64

Páginas: 3751-3762

Tipo: Artículo

DOI: 10.1016/J.MED.2018.10.002 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumen

Resumen La neumonía adquirida en la comunidad (NAC) o extrahospitalaria se define como una infección aguda del parénquima pulmonar que afecta a sujetos inmunocompetentes no hospitalizados, y que se caracteriza por la presencia de fiebre junto con síntomas respiratorios, así como por la existencia de infiltrados pulmonares en la radiografía de tórax no explicados por otra causa, siendo por tanto imprescindible la realización de esta última para establecer el diagnóstico de la enfermedad. Su incidencia en España se sitúa entre el 5 y el 11% de la población adulta. El diagnóstico sindrómico de NAC se basa en la existencia de una clínica de infección aguda, acompañada de un infiltrado pulmonar de reciente aparición en la radiografía de tórax. La clasificación de la enfermedad en función de la gravedad es fundamental para establecer el tratamiento. El tratamiento antibiótico de la NAC es fundamentalmente empírico en la mayoría de los casos, debiéndose iniciar lo más rápidamente posible, con el fin de conseguir una reducción de la morbimortalidad. Community-acquired pneumonia (CAP) or out-of-hospital pneumonia is defined as an acute lung parenchyma infection concerning immunocompetent non-hospitalized patients. Clinical features are fever and respiratory symptoms, as well as demonstrable lung infiltrate not explained by another cause; a chest radiograph is necessary in order to establish the diagnosis of CAP and to differentiate it from other respiratory illnesses. In Spain, its incidence ranges among 5% to 11% of adult population. Syndromic diagnosis is based on clinical features of acute infection and in the presence of a pulmonary infiltrate revealed by chest radiography. Most CAP patients are treated with antibiotics empirically and, in order to reduce morbidity and mortality, it has to be early administrated.

€ Ver financiación

Información de financiación

This work was financially supported by the Russian Foundation for Basic Research (Project No. 98-03-32079) and by the Russian Foundation for Basic Research and INTAS (Grant No. 95-01631.

Financiadores

Referencias bibliográficas

  • Almirall J, Bolibar I, Vidal J, Sauca G, Coll P, Niklasson B. Epidemiology of community-acquired pneumonia in adults: a population-ba-sed study. Eur Respir J. 2000;15:757-63.
  • Almirall J, Bolibar I, Balanzo X, González CA. Risk factors for community acquired pneumonia in adults: a population-based case-control study. Eur Respir J. 1999;13:349-55.
  • Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA. Prognosis and outcomes of patients with community-acquired pneu-monia. A meta-analysis. JAMA. 1996;275:134-41.
  • Alkhayer M, Jenkins PF, Harrison BD. The outcome of community acquired pneumonia treated on the intensive care unit. Repir Med. 1990;84:13-6.
  • File TM. Community-acquired pneumonia. Lancet. 2003;362:1991-2001.
  • Garau J, Calbo E. Community acquired pneumonia. Lancet. 2008;371: 455-8.
  • Johnstone J, Majumdar SR, Fox JD, Marrie TJ. Viral infection in adult hospitalizated with community-acquired pneumonia: prevalence, pathogens, and presentation. Chest. 2008;134:1141-48.
  • Stralin K. Usefulness of aetiological tests for guiding antibiotic therapy in community-acquired pneumonia. Int J Antimicrob Agents. 2008;31:3-11.
  • Miyashita N, Shimizu H, Ouchi K, Kawasaki K, Kawai Y, Obase Y. Assessment of the usefulness of sputum Gram stain and culture for diagnosis of community-acquired pneumonia requiring hospitalization. Med Sci Monit. 2008;14:CR171-6.
  • Molinos L. Detection of antigens in urine. Arch Bronconeumol. 2006; 42:101-3.
  • Menéndez R, Torres A, Aspa J, Capelastegui A, Prat C, Rodríguez de Castro F. Normativas para el diagnóstico y el tratamiento de la neumonía adquirida en la comunidad. Sociedad Española de Neumología y Cirugía Torácica (SEPAR). Arch Bronconeumol. 2010;46:543-58.
  • Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE. Aprediction rule to identify low risk patients with community acquired pneumonia. N Engl J Med. 1997;336:243-50.
  • Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377-82.
  • Bauer TT, Ewig S, Marre R, Suttorp N, Welte T. CRB-65 predicts death from community acquired pneumonia. J Intern Med. 2006;260:93-101.
  • Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community acquired pneumonia in adults. Clin Infect Dis. 2007; 44Suppl2:S27-72
  • Charles PG, Wolfe R, Whitby M, Fine MJ, Fuller AJ, Stirling R. SMARTCOP: A tool for predicting the need for intensive respiratory or vasopressor support in community acquired pneumonia. Clin Infect Dis. 2008;47:375-84.
  • España PP, Capelastegui A, Gorordo I, Esteban C, Oribe M, Ortega M. Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Respir Crit Care Med. 2006; 174:1249-56.
  • Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG. Timing of antibiotic administration and outcomes for medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med. 2004;164:637-44.
  • Halm EA, Teirstein AS. Clinical practice. Management of community-acquired pneumonia. N Engl J Med. 2002;347:2039-45.
  • Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community acquired pneumonia. Arch Intern Med. 2004;164:637-44.
  • Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64Suppl3: iii1-55.
  • Uranga A, España PP, Bilbao A, Quintana JM, Arriaga I, Intxausti M. Duration of antibiotic treatment in community acquired pneumonia: a multicenter randomized clinical trial. JAMA Intern Med. 2016;176(9): 1257-65
  • Menéndez R, Torres A, Rodríguez de Castro F, Zalacaín R, Aspa J, Martín Villasclaras JJ. Reaching stability in community acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin Infect Dis. 2004;39:1783-90.
  • Menéndez R, Torres A. Treatment failure in community-acquired pneumonia. Chest. 2007;32:1348-55.
  • Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community acquired pneumonia. Am J Med. 2008;121:219-25
  • Menéndez R, Cavalcanti M, Reyes S, Mensa J, Martínez R, Marcos MA. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax. 2008;63:447-52.
Fuente de los datos: Dialnet